Preclinical data published in Vaccine on Dutch biotech Mucosis' nasal flu vaccine showed that it protected mice against infection with the flu virus. In addition, it may also reduce the amount of virus that is shed, lowering the chance of the bug being passed on. Mucosis is developing FluGEM with corporate, governmental and non-governmental partners, and it started Phase I trials in healthy adults and elderly people last year. The vaccine combines traditional inactivated influenza antigens with its Mimopath technology--bacterium-like particles based on Lactococcus lactis, which is used in the food industry. Press release